Akebia says three-times-weekly vadadustat met primary endpoint of non-inferiority to Mircera in dialysis patients

Akebia said its three-times-weekly vadadustat met the primary endpoint of non-inferiority to Mircera in hemoglobin control in dialysis patients.

Detected & updated continuously · Source: Nebula